These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1845208)

  • 21. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    O'Connor PJ; Rush WA; Trence DL
    J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients.
    Samman A; Imai C; Straatman L; Frolich J; Humphries K; Ignaszewski A
    J Heart Lung Transplant; 2005 Aug; 24(8):1008-13. PubMed ID: 16102434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)].
    Miyake N; Iizuka K
    Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
    Vivekananthan K; Mehra MR; Uber PA; DeGruiter H; Lavie CJ; Milani RV
    J Assoc Physicians India; 2002 May; 50(5):682-4. PubMed ID: 12186124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].
    Strano A; Novo S; Notarbartolo A; Davì G; Abrignani MG; Alaimo G; Averna MR; Barbagallo CM; Marino G
    Cardiologia; 1989 Dec; 34(12):1027-33. PubMed ID: 2634479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients.
    Kirsten R; Heintz B; Nelson K; Hesse K; Schneider E; Oremek G; Nemeth N
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):53-6. PubMed ID: 8004358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
    Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
    Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
    Alcocer L; Fernández L; Campos E; Más R
    Int J Tissue React; 1999; 21(3):85-92. PubMed ID: 10645516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acipimox treatment of hyperlipidemia type II].
    Noseda G; Fragiacomo C; Cairoli R
    Schweiz Med Wochenschr; 1982 Dec; 112(49):1790-1. PubMed ID: 6758114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term bezafibrate treatment in a lipid clinic].
    Yeshurun D; Abukarshin R; Ellias N; Naschitz JE
    Harefuah; 1992 May; 122(10):632-4, 687. PubMed ID: 1526540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study with a new antihyperlipemic combination].
    Pistautz H
    Arzneimittelforschung; 1977; 27(1):152-6. PubMed ID: 576816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
    Barlow CW; Soicher ER; Jankelow D; Myburgh DP
    S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia].
    Lisch HJ; Sailer S; Braunsteiner H
    Arzneimittelforschung; 1977; 27(10):2017-20. PubMed ID: 579116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].
    Rajecová E; Kréze A; Klimes I; Cvrkalová A; Lacko A; Langrová H; Hanzen E
    Cas Lek Cesk; 1991 Nov; 130(22-23):661-3. PubMed ID: 1786587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Procetofen, a new lipid- and urine-acid-reducing substance].
    Matzkies F; Schulzky D; Berg G
    Fortschr Med; 1978 Oct; 96(38):1939-41. PubMed ID: 700582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.